Influenza and Other Respiratory Viruses

Article	Citations
Respiratory syncytial virus disease burden in adults aged 60 years and older in high‐income countries: A systematic literature review and meta‐analysis	149
COVID‐19 vaccine hesitancy and attitudes in Qatar: A national cross‐sectional survey of a migrant‐majority population	122
Increased risk of rhinovirus infection in children during the coronavirus disease‐19 pandemic	104
COVID‐19 severity from Omicron and Delta SARS‐CoV‐2 variants	70
Effectiveness of the MF59‐adjuvanted trivalent or quadrivalent seasonal influenza vaccine among adults 65 years of age or older, a systematic review and meta‐analysis	64
Early epidemiological investigations: World Health Organization UNITY protocols provide a standardized and timely international investigation framework during the COVID‐19 pandemic	58
Defining the seasonality of respiratory syncytial virus around the world: National and subnational surveillance data from 12 countries	57
The economic burden of influenza among adults aged 18 to 64: A systematic literature review	54
Which influenza viruses will emerge following the SARS‐CoV‐2 pandemic?	50
International changes in respiratory syncytial virus (RSV) epidemiology during the COVID‐19 pandemic: Association with school closures	44
Admission respiratory status predicts mortality in COVID‐19	43
The immunogenicity and safety of respiratory syncytial virus vaccines in development: A systematic review	43
The impact of the 2009 influenza pandemic on the seasonality of human respiratory syncytial virus: A systematic analysis	36
Associations between persistent symptoms after mild COVID‐19 and long‐term health status, quality of life, and psychological distress	35
Change in functional status associated with respiratory syncytial virus infection in hospitalized older adults	33
Cost determinants among adults hospitalized with respiratory syncytial virus in the United States, 2017–2019	30
Impact of coronavirus disease 2019 on respiratory surveillance and explanation of high detection rate of human rhinovirus during the pandemic in the Republic of Korea	27
Using the health belief model to identify barriers to seasonal influenza vaccination among Australian adults in 2019	27
Transmission of SARS‐CoV‐2 during a 2‐h domestic flight to Okinawa, Japan, March 2020	27
The burden of seasonal influenza in Italy: A systematic review of influenza‐related complications, hospitalizations, and mortality	25
Antibody responses to COVID‐19 vaccination in people with obesity: A systematic review and meta‐analysis	25
Estimating the burden of adult hospital admissions due to RSV and other respiratory pathogens in England	25
Global patterns of seasonal influenza activity, duration of activity and virus (sub)type circulation from 2010 to 2020	24
Impact of varying wave periods of COVID‐19 on in‐hospital mortality and length of stay for admission through emergency department: A territory‐wide observational cohort study	23
Re‐emergence of influenza virus circulation during 2020 in parts of tropical Asia: Implications for other countries	22

Novel and extendable genotyping system for human respiratory syncytial virus based on whole‐genome sequence analysis	21
The role of non‐pharmaceutical interventions on influenza circulation during the COVID‐19 pandemic in nine tropical Asian countries	21
Epidemiological and clinical features of SARS‐CoV‐2 infection in children during the outbreak of Omicron variant in Shanghai, March 7–31, 2022	21
Delayed respiratory syncytial virus outbreak in 2020 in Taiwan was correlated with two novel RSV‐A genotype ON1 variants	21
Epidemiological and clinical characteristics of respiratory syncytial virus and influenza infections in hospitalized children before and during the COVID‐19 pandemic in Central China	20
Absence of association between 2019‐20 influenza vaccination and COVID‐19: Results of the European I‐MOVE‐COVID‐19 primary care project, March‐August 2020	20
Household transmission of COVID‐19 among the earliest cases in Antananarivo, Madagascar	20
The COVID‐19 epidemic in Madagascar: clinical description and laboratory results of the first wave, march‐september 2020	19
Population‐based assessment of risks for severe COVID‐19 disease outcomes	19
Factors associated with COVID‐19 related hospitalisation, critical care admission and mortality using linked primary and secondary care data	18
Symptoms and recovery among adult outpatients with and without COVID‐19 at 11 healthcare facilities—July 2020, United States	18
Burden and severity of children's hospitalizations by respiratory syncytial virus in Portugal, 2015–2018	18
Differentiating impacts of non‐pharmaceutical interventions on non‐coronavirus disease‐2019 respiratory viral infections: Hospital‐based retrospective observational study in Taiwan	18
Influenza vaccine effectiveness against influenza A subtypes in Europe: Results from the 2021–2022 I‐MOVE primary care multicentre study	18
Comparative assessment of reported symptoms of influenza, respiratory syncytial virus, and human metapneumovirus infection during hospitalization and post‐discharge assessed by Respiratory Intensity a	18
Estimating the burden of influenza‐related and associated hospitalizations and deaths in France: An eight‐season data study, 2010–2018	18
Clinical manifestations of COVID‐19 differ by age and obesity status	18
Ascertainment of vaccination status by self‐report versus source documentation: Impact on measuring COVID‐19 vaccine effectiveness	18
Risk factors and medical resource utilization in US adults hospitalized with influenza or respiratory syncytial virus in the Hospitalized Acute Respiratory Tract Infection study	18
A Sanger sequencing protocol for SARS‐CoV‐2 S‐gene	17
Type I interferon autoantibodies in hospitalized patients with Middle East respiratory syndrome and association with outcomes and treatment effect of interferon beta‐1b in MIRACLE clinical trial	17
Predictors of all‐cause mortality among patients hospitalized with influenza, respiratory syncytial virus, or SARS‐CoV‐2	16
Determination of respiratory syncytial virus epidemic seasons by using 95% confidence interval of positivity rates, 2011–2021, Germany	16
ROSES‐S: Statement from the World Health Organization on the reporting of seroepidemiologic studies for SARS‐CoV‐2	16
Occurrence and disease burden of respiratory syncytial virus and other respiratory pathogens in adults aged ≥65 years in community: A prospective cohort study in Japan	16
Risk of symptomatic COVID‐19 due to aircraft transmission: a retrospective cohort study of contact‐traced flights during England’s containment phase	16
Risk factors for outbreaks of COVID‐19 in care homes following hospital discharge: A national cohort analysis	16
Severe acute respiratory syndrome coronavirus 2 can be detected in exhaled aerosol sampled during a few minutes of breathing or coughing	15
Cohort profile: A Prospective Household cohort study of Influenza, Respiratory syncytial virus and other respiratory pathogens community burden and Transmission dynamics in South Africa, 2016–2018	15
Viral epidemiology and SARS‐CoV‐2 co‐infections with other respiratory viruses during the first COVID‐19 wave in Paris, France	15
Comparison of the risk of hospitalisation among BA.1 and BA.2 COVID‐19 cases treated with sotrovimab in the community in England	14
Impact of respiratory syncytial virus disease on quality of life in adults aged ≥50 years: A qualitative patient experience cross‐sectional study	14
National seroepidemiological study of COVID‐19 after the initial rollout of vaccines: Before and at the peak of the Omicron‐dominant period in Japan	14
Clinical characteristics and population‐based attack rates of respiratory syncytial virus versus influenza hospitalizations among adults—An observational study	14
Seasonal influenza in children: Costs for the health system and society in Europe	14
No evidence for HPAI H5N1 2.3.4.4b incursion into Australia in 2022	14
Population‐based hospitalization burden estimates for respiratory viruses, 2015–2019	14
Epidemiology of acute lower respiratory tract infection hospitalizations in Thai children: A 5‐year national data analysis	14
Role of age and birth month in infants hospitalized with RSV‐confirmed disease in the Valencia Region, Spain	13
Diagnostic performance of COVID‐19 serological assays during early infection: A systematic review and meta‐analysis of 11 516 samples	13
Respiratory syncytial virus in pediatric influenza‐like illness cases in Lombardy, Northern Italy, during seven consecutive winter seasons (from 2014–2015 to 2020–2021)	13
Oseltamivir treatment of influenza A and B infections in infants	13
Record high parainfluenza season in children after relaxation of COVID‐19 restrictions in fall 2021—A nationwide register study in Finland	13
Epidemiological analysis of the first 1000 cases of SARS‐CoV‐2 lineage BA.1 (B.1.1.529, Omicron) compared with co‐circulating Delta in Wales, UK	13
Systematic literature review of the signs and symptoms of respiratory syncytial virus	13
Household transmission of SARS‐CoV‐2 during the Omicron wave in Shanghai, China: A case‐ascertained study	13
Acute respiratory infection emergency access in a tertiary care children hospital in Italy, prior and after the SARS‐CoV‐2 emergence	12
Upsurge of human rhinovirus infection followed by a delayed seasonal respiratory syncytial virus infection in Thai children during the coronavirus pandemic	12
Safety and efficacy of AK0529 in respiratory syncytial virus‐infected infant patients: A phase 2 proof‐of‐concept trial	12
The REinfection in COVID‐19 Estimation of Risk (RECOVER) study: Reinfection and serology dynamics in a cohort of Canadian healthcare workers	12

Effectiveness of two and three mRNA COVID‐19 vaccine doses against Omicron‐ and Delta‐Related outpatient illness among adults, October 2021–February 2022	12
Impact of respiratory viral infections on mortality and critical illness among hospitalized patients with chronic obstructive pulmonary disease	12
Comparative incidence and burden of respiratory viruses associated with hospitalization in adults in New York City	12
All‐cause versus cause‐specific excess deaths for estimating influenza‐associated mortality in Denmark, Spain, and the United States	12
Human respiratory syncytial virus diversity and epidemiology among patients hospitalized with severe respiratory illness in South Africa, 2012–2015	12
Respiratory syncytial virus seasonality in three epidemiological zones of Kenya	12
Public health and social measures during health emergencies such as the COVID‐19 pandemic: An initial framework to conceptualize and classify measures	12
Epidemiology of SARS‐CoV‐2 infection and SARS‐CoV‐2 positive hospital admissions among children in South Africa	11
Effect of COVID‐19 vaccine on menstrual experience among females in six Arab countries: A cross sectional study	11
COVID‐19 outbreaks in aged‐care facilities in Australia	11
Comparative hospitalization risk for SARS‐CoV‐2 Omicron and Delta variant infections, by variant predominance periods and patient‐level sequencing results, New York City, August 2021–January 2022	11
Relative timing of respiratory syncytial virus epidemics in summer 2021 across the United States was similar to a typical winter season	11
Estimating SARS‐CoV‐2 infections and associated changes in COVID‐19 severity and fatality	11
Trends in seroprevalence of SARS‐CoV‐2 and infection fatality rate in the Norwegian population through the first year of the COVID‐19 pandemic	11
The importance of influenza vaccination during the COVID‐19 pandemic	10
Prevalence and seasonality of viral respiratory infections in a temperate climate region: A 24‐year study (1997–2020)	10
Neurological complications associated with influenza in hospitalized children	10
Interactions among common non‐SARS‐CoV‐2 respiratory viruses and influence of the COVID‐19 pandemic on their circulation in New York City	10
Changes in virus detection in hospitalized children before and after the severe acute respiratory syndrome coronavirus 2 pandemic	10
SERS‐based immunomagnetic bead for rapid detection of H5N1 influenza virus	10
Developing a sampling methodology for timely reporting of population‐based COVID‐19‐associated hospitalization surveillance in the United States, COVID‐NET 2020–2021	10
Burden of respiratory syncytial virus in adults in the United Kingdom: A systematic literature review and gap analysis	9
Effectiveness of first and second COVID‐19 mRNA vaccine monovalent booster doses during a period of circulation of Omicron variant sublineages: December 2021–July 2022	9
The national burden of influenza‐like illness and severe respiratory illness overall and associated with nine respiratory viruses in South Africa, 2013–2015	9
A comparison of coronavirus disease 2019 and seasonal influenza surveillance in five European countries: France, Germany, Italy, Spain and the United Kingdom	9
Independent association between meteorological factors, PM2.5, and seasonal influenza activity in Hangzhou, Zhejiang province, China	9
Nirsevimab Effectiveness Against Cases of Respiratory Syncytial Virus Bronchiolitis Hospitalised in Paediatric Intensive Care Units in France, September 2023–January 2024	9
The effect of nirmatrelvir‐ritonavir on viral clearance and length of hospital stay in patients infected with SARS‐CoV‐2 omicron variants	9
Seasonal respiratory virus circulation was diminished during the COVID‐19 pandemic	9
Bacterial and viral infections among adults hospitalized with COVID‐19, COVID‐NET, 14 states, March 2020–April 2022	9
Some characteristics of clinical sequelae of COVID‐19 survivors from Wuhan, China: A multi‐center longitudinal study	9
Respiratory syncytial virus‐associated acute respiratory illness in adult non‐immunocompromised patients: Outcomes, determinants of outcomes, and the effect of oral ribavirin treatment	9
Influenza hospitalizations in Australian children 2010–2019: The impact of medical comorbidities on outcomes, vaccine coverage, and effectiveness	8
Implications of the unexpected persistence of human rhinovirus/enterovirus during the COVID‐19 pandemic in Canada	8
Prevalence of antibodies against SARS‐CoV‐2 in the Norwegian population, August 2021	8
Pronounced antibody elevation after SARS‐CoV‐2 BNT162b2 mRNA booster vaccination in nursing home residents	8
The Oregon Child Absenteeism Due to Respiratory Disease Study (ORCHARDS): Rationale, objectives, and design	8
Estimating the serial intervals of SARS‐CoV‐2 Omicron BA.4, BA.5, and BA.2.12.1 variants in Hong Kong	8
Transmission of SARS‐CoV‐2 in standardised first few X cases and household transmission investigations: A systematic review and meta‐analysis	8
Live SARS‐CoV‐2 is difficult to detect in patient aerosols	8
Epidemiology and outcome of influenza‐associated infections among hospitalized patients with acute respiratory infections, Egypt national surveillance system, 2016‐2019	8
Consistency of self‐reported and documented historical influenza vaccination status of US healthcare workers	8
mRNA COVID‐19 vaccine effectiveness against SARS‐CoV‐2 infection in a prospective community cohort, rural Wisconsin, November 2020 to December 2021	8
Molecular epidemiology of Enteroviruses and Rhinoviruses in patients with acute respiratory infections in Yaounde, Cameroon	8
Modelling the influenza disease burden in people aged 50–64 and ≥65 years in Australia	8
Zanamivir aqueous solution in severe influenza: A global Compassionate Use Program, 2009–2019	8
A remote household‐based approach to influenza self‐testing and antiviral treatment	8
Factors associated with early uptake of COVID‐19 vaccination among healthcare workers in Azerbaijan, 2021	8
Clinical and socioeconomic burden of rhinoviruses/enteroviruses in the community	8
Predictors of influenza severity among hospitalized adults with laboratory confirmed influenza: Analysis of nine influenza seasons from the Valencia region, Spain	8
Seasonal and inter‐seasonal RSV activity in the European Region during the COVID‐19 pandemic from autumn 2020 to summer 2022	8
Behavioral factors associated with SARS‐CoV‐2 infection in Japan	8
Incidence, hospitalization, and mortality in children aged 5 years and younger with respiratory syncytial virus‐related diseases: A systematic review and meta‐analysis	7
Genomic surveillance of SARS‐CoV‐2 strains circulating in Iran during six waves of the pandemic	7
Underlying cardiopulmonary conditions as a risk factor for influenza and respiratory syncytial virus infection among community‐dwelling adults aged ≥ 65 years in Thailand: Findings from a two‐year pro	7
Prior SARS‐CoV‐2 infection and COVID‐19 vaccine effectiveness against outpatient illness during widespread circulation of SARS‐CoV‐2 Omicron variant, US Flu VE network	7
SARS‐CoV‐2 infections in households in a peri‐urban community of Lima, Peru: A prospective cohort study	7
Investigating confounding in network‐based test‐negative design influenza vaccine effectiveness studies—Experience from the DRIVE project	7
A mixed methods study of seasonal influenza vaccine hesitancy in adults with chronic respiratory conditions	7
Antibody titres elicited by the 2018 seasonal inactivated influenza vaccine decline by 3 months post‐vaccination but persist for at least 6 months	7
Prevalence of chronic conditions and influenza vaccination coverage rates in Germany: Results of a health insurance claims data analysis	7
Influenza surveillance systems using traditional and alternative sources of data: A scoping review	7
Association between COVID‐19 and consistent mask wearing during contact with others outside the household—A nested case–control analysis, November 2020–October 2021	7
Low prevalence of seasonal influenza viruses in Hong Kong, 2022	7
Attitudes, beliefs and practice of Egyptian healthcare workers towards seasonal influenza vaccination	7
Incidence and seasonality of respiratory viruses among medically attended children with acute respiratory infections in an Ecuador birth cohort, 2011–2014	6
Symptom‐based case definitions for COVID‐19: Time and geographical variations for detection at hospital admission among 260,000 patients	6
Viral replication dynamics could critically modulate vaccine effectiveness and should be accounted for when assessing new SARS‐CoV‐2 variants	6
Age‐specific severity of severe acute respiratory syndrome coronavirus 2 in February 2020 to June 2021 in the Netherlands	6
SARS‐CoV‐2 infection‐induced immunity and the duration of viral shedding: Results from a Nicaraguan household cohort study	6
Lower cognitive scores among toddlers in birth cohorts with acute respiratory illnesses, fevers, and laboratory‐confirmed influenza	6
Comparative analysis of mortality in patients admitted with an infection with influenza A/B virus, respiratory syncytial virus, rhinovirus, metapneumovirus or SARS‐CoV‐2	6
Facing the future of respiratory virus surveillance: “The mosaic surveillance framework”	6
COVID‐19 vaccination status and testing rates in Finland—A potential cause for bias in observational vaccine effectiveness analysis	6
Domination of influenza vaccine virus strains in Hong Kong, 2021	6
Multi‐decade national cohort identifies adverse pregnancy and birth outcomes associated with acute respiratory illness hospitalisations during the influenza season	6
Estimating SARS‐CoV‐2 transmission in educational settings: A retrospective cohort study	6
Persistence of racial/ethnic and socioeconomic status disparities among non‐institutionalized patients hospitalized with COVID‐19 in Connecticut, July to December 2020	6
Epidemiology and seasonality of human parainfluenza serotypes 1‐3 in Australian children	6
Respiratory syncytial virus and other respiratory virus infections in residents of homeless shelters – King County, Washington, 2019–2021	6

Incidence of SARS‐CoV‐2 infection among COVID‐19 vaccinated and unvaccinated healthcare personnel, first responders, and other essential and frontline workers: Eight US locations, January–September 20	6
Characterization of influenza seasonality in China, 2010–2018: Implications for seasonal influenza vaccination timing	6
Anti‐SARS‐CoV‐2 IgG antibody levels among Thai healthcare providers receiving homologous and heterologous COVID‐19 vaccination regimens	6
The accuracy of reverse genetics systems for SARS‐CoV‐2: Circular polymerase extension reaction versus bacterial artificial chromosome	6